Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage
biopharmaceutical company developing potential best-in-class oncology
therapies, today announced the on-line publication of preclinical
results for RX-3117...
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced the on-line publication of preclinical results for RX-3117 in a peer reviewed medical journal, Investigational New Drugs, in an article titled, “Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)”. Investigational New Drugs is an interdisciplinary journal presenting the latest investigations and discussions of critical questions appropriate to the entire field of new anticancer drug development. Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer, commented, “The broad spectrum of anti-tumor activity against human cancer cell lines, oral bioavailability in cancer patients, and improved preclinical and clinical safety profile suggest that RX-3117 may represent a major advance in the treatment of solid cancer tumors. Rexahn anticipates initiating a Phase I clinical study in cancer patients with solid tumors in the fourth quarter of 2013.” The published study characterized the broad spectrum of potent anti-tumor effects of RX-3117 against 50 different human cancer cell lines (including colon, lung, renal and pancreas) and its unique mechanism of activation in cancer cells. In addition, RX-3117 was shown to be effective in gemcitabine resistant human cancer cell lines. Although RX-3117 shares some properties with other nucleoside compounds such as gemcitabine, its cytotoxicity profile, metabolism and mechanism of action make it distinct and potentially clinically superior to existing nucleoside compounds. Prof. Dr. Godefridus J. (Frits) Peters, Head Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands, and lead author of the published results, commented, “RX-3117 is an exciting new nucleoside analog with unique properties both regarding its mechanism of action and its pharmacology. Its excellent oral bioavailability fits very well with the current tendency to give anticancer drugs orally. Its mechanism of action gives several leads for future combination therapies with different drugs.”